-
Krishna M Ella, Bharat Biotech, CMD, said, “With prior expertise in malaria research, WHO prequalified vaccines, supplied to more than 70 countries, Bharat Biotech is geared up for large-scale manufacturing.
-
Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
-
This is India's first and only phase-3 efficacy study for a Covid-19 vaccine, and the largest phase-3 efficacy trial ever conducted for any vaccine in the country.
-
The company was given a fresh letter of comfort recently for supplying another 45 lakh doses of Covaxin. The doses will be dispatched as when the Ministry places orders with the company
-
According to an industry expert, the company is liable to pay compensation to people in case of serious side effects caused by the vaccine administered while in the clinical trial mode
-
Zilla Parishad Chairperson Roja Sharma was speaking after launching the vaccination drive at Area Hospital, Siddipet on Saturday
-
Hyderabad: Governor Dr Tamilisai Soundararajan on Saturday launched the Covid vaccination programme for the frontline workers at Nizam’s Institute of Medical Sciences (NIMS). She appealed to all the frontline warriors and others to take the vaccine with confidence as the vaccines were developed and cleared as per strict safety norms adhering to international standards. “Our […]
-
58 healthcare centres ready to provide emergency services to individuals with Adverse Events Following Immunisation across State
-
After having received the government purchase order for 55 lakh doses, Bharat Biotech shipped the first batch of vaccines (each vial containing 20 doses) to Gannavaram, Guwahati, Patna, Delhi, Kurukshetra, Bengaluru
-
"Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects are negligible"
-
The supplies of Covaxin will be prioritised for public market through direct procurement by Brazil government while the supplies to private market would be based upon receipt of market authorisation from the country's regulator
-
The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.
-
Says final decision with government, all norms followed in vaccine approval
-
The Drugs Controller General of India (DCGI) on Sunday approved Oxford COVID-19 vaccine Covishield
-
The Drugs Controller General of India on Sunday gave the permission to Bharat Biotech's Covaxin for use in an emergency situation.
-
The approval to Covaxin has been questioned by industry experts and some opposition Congress leaders who have expressed concern over the absence of phase 3 trial data
-
The Brazilian Association of Vaccine Clinics (ABCVAC) confirmed on its website it had signed a memorandum of understanding with the Indian firm to purchase its Covaxin vaccine
-
It was not just the invisible pathogen that engaged scientists in 2020 but also the vast expanse of the cosmos
-
"Following the emergency use permission, the company is in a position to meet any production requirement that the government may have at this time,” company officials said
-
While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. Covaxin has generated excellent safety data with robust immune responses